Table 1 Characteristics of the included studies
No. auther/study | COR | CR | timing of non-IRA intervention | Indication of non-IRA intervention | timing of study | number of centers | primary endpoint | secondary endpoint | stent type | ollow-up | Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
1. Ghani et al. [17] | 41 | 80 | During the in-hospital phase after primary PCI or in an outpatient setting but no later than 3 weeks after STEMI | FFR < 0.75 Or Diameter stenosis> 90% | From June 2004 to February 2007 | Single center | Ejection fraction at 6 months | MACE including death, non-fatal re-infarction, and additional revascularization | BMS 68% DES 20% PTCA12% | 3 years | During procedure: glycoprotein IIb/IIIa inhibitors(45%). At discharge: not mentioned |
2.DANAMI-3- PRIMULTI [19] | 313 | 314 | Two days after the initial PCI procedure and before discharge | FFR ≤ 0.80 Or Diameter stenosis> 90% | From March 2011 to February 2014 | 2 centers | A composite of all-cause mortality, re-infarction, and ischemia-driven revascularization in the non-IRA | Components of the primary endpoint, cardiac death, and PCI in the non-IRA | BMS 1.5% DES 94% PTCA5% | 27 months (12–44 months) | During procedure: glycoprotein IIb/IIIa inhibitors(20%), bivalirudin(75%). At discharge: clopidogrel 12–14% Prasugrel 62–65% Ticagrelor 21–23% |
3.COMPAREACUTE [20] | 590 | 590,295 | During index PCI procedure (83.4%) Delayed during index hospitalization (16.6%) | FFR ≤ 0.80 | From July 2011 to October 2015 | 24 centers | the composite of all-cause mortality, nonfatal myocardial infarction, any revascularizatio n, and cerebrovascular | Components of the primary endpoints at 24,36 month s | BMS 0.6% DES 98.8% PTCA0.6% | 36 months | During procedure: not mentioned At discharge: accordance with contemporary guidelines. |